Key Points
- CRISPR Therapeutics General Counsel James Kasinger sold 1,990 shares at an average price of $60.04, for total proceeds of $119,479.60. He retained 94,784 shares valued at approximately $5.69 million, reducing his ownership by 2.06%.
- CRSP recently traded at $50.44, with a market capitalization of approximately $4.88 billion and a 52-week range of $44.12 to $78.38. Its latest quarter showed a loss of $0.94 per share on $10.18 million in revenue.
- Analysts hold a consensus “Moderate Buy” rating with an average price target of $67.94, while institutional investors own 69.20% of the company’s shares.
CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) General Counsel James Kasinger sold 1,990 shares of CRISPR Therapeutics stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $60.04, for a total value of $119,479.60. Following the completion of the transaction, the general counsel directly owned 94,784 shares of the company's stock, valued at $5,690,831.36. This represents a 2.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
CRISPR Therapeutics Stock Performance
NASDAQ:CRSP opened at $50.44 on Friday. The company has a market cap of $4.88 billion, a price-to-earnings ratio of -10.60 and a beta of 1.76. CRISPR Therapeutics AG has a fifty-two week low of $44.12 and a fifty-two week high of $78.38. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.85 and a current ratio of 17.85. The stock has a fifty day moving average price of $55.03 and a 200-day moving average price of $53.08.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, June 30th. The company reported ($0.94) EPS for the quarter. The company had revenue of $10.18 million during the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%. As a group, equities analysts anticipate that CRISPR Therapeutics AG will post -4.47 EPS for the current fiscal year.
Analyst Ratings Changes
Several research firms have commented on CRSP. Citizens Jmp reissued a "market outperform" rating and issued a $80.00 target price on shares of CRISPR Therapeutics in a report on Monday, August 31st. Needham & Company LLC reaffirmed a "buy" rating and set a $82.00 price target on shares of CRISPR Therapeutics in a report on Monday, August 31st. Weiss Ratings reiterated a "sell (d-)" rating on shares of CRISPR Therapeutics in a research report on Friday, July 17th. Morgan Stanley set a $60.00 price objective on shares of CRISPR Therapeutics and gave the company an "equal weight" rating in a research note on Thursday, June 11th. Finally, William Blair upgraded shares of CRISPR Therapeutics to a "strong-buy" rating in a research report on Wednesday, September 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $67.94.
Read Our Latest Analysis on CRISPR Therapeutics
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. Versant Capital Management Inc increased its holdings in CRISPR Therapeutics by 175.1% in the 2nd quarter. Versant Capital Management Inc now owns 465 shares of the company's stock worth $25,000 after purchasing an additional 296 shares in the last quarter. Sunbelt Securities Inc. raised its position in CRISPR Therapeutics by 4.5% in the first quarter. Sunbelt Securities Inc. now owns 7,843 shares of the company's stock valued at $373,000 after purchasing an additional 336 shares during the last quarter. D.A. Davidson & CO. boosted its stake in shares of CRISPR Therapeutics by 5.9% during the first quarter. D.A. Davidson & CO. now owns 6,324 shares of the company's stock valued at $301,000 after purchasing an additional 353 shares in the last quarter. Kestra Advisory Services LLC boosted its stake in shares of CRISPR Therapeutics by 2.0% during the first quarter. Kestra Advisory Services LLC now owns 21,052 shares of the company's stock valued at $1,001,000 after purchasing an additional 416 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in shares of CRISPR Therapeutics by 6.3% during the first quarter. PNC Financial Services Group Inc. now owns 8,202 shares of the company's stock worth $390,000 after purchasing an additional 489 shares during the last quarter. Institutional investors own 69.20% of the company's stock.
CRISPR Therapeutics Company Profile
(
Get Free Report)
CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines based on CRISPR/Cas9 technology. The company aims to treat serious diseases by precisely modifying genetic material in patients' cells, with research programs spanning hematology, oncology, autoimmune diseases, and regenerative medicine.
Its lead product, CASGEVY (exagamglogene autotemcel), is a CRISPR/Cas9-based cell therapy developed with Vertex Pharmaceuticals. CASGEVY is approved in multiple markets, including the United States, United Kingdom, and European Union, for certain patients with sickle cell disease and transfusion-dependent beta thalassemia.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
